GLP-1 drug used for diabetes, obesity and more
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Lilly has filed six lawsuits targeting online sellers and clinics marketing retatrutide, a GLP-1 drug still in Phase 3 trials for obesity and diabetes, while US authorities report a surge in illicit shipments. The company says products sold online are unverified and unapproved, and warns of substantial health risks.
PMOS, previously grouped with PCOS, affects about 1 in 8 women and involves insulin resistance and testosterone imbalance. Case studies show GLP-1 medications may improve symptoms and menstrual regularity, with trials underway. Diagnosis remains challenging and access to new treatments will depend on healthcare systems.
A BBC Business report notes rising use of weight-loss drugs in 2024-25, with a focus on male users and safety concerns, while other outlets explore personal journeys with GLP-1 medications and gut health trends.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Lawsuits allege GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can cause permanent vision loss. Novo Nordisk and Eli Lilly dispute the claims as regulators review data; meanwhile trials and studies show mixed signals about risk.